Meglucon (Metformin Hydrochloride)

Metformin reduces the liver’s production of glucose, decreases the amount of glucose absorbed from the intestine, and enhances the sensitivity of muscle and fat cells to insulin, which together lower blood sugar levels without increasing insulin secretion.

The dose of Meglucon is individualized by the prescribing clinician based on the patient’s clinical condition, renal function, and response to therapy. The prescriber determines the appropriate strength, frequency, and titration schedule.

Meglucon is classified as Pregnancy Category B, indicating no evidence of risk in animal studies and a lack of well‑controlled studies in pregnant women. It may be used if the potential benefit justifies the potential risk. Breastfeeding mothers should consult their physician, as metformin does pass into breast milk in small amounts.

To place an order, submit an enquiry on the Meglucon product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Meglucon (metformin) belongs to the biguanide class and is often first‑line therapy because it improves insulin sensitivity without causing weight gain. Compared with sulfonylureas, it carries a lower risk of hypoglycemia, and unlike insulin, it is administered orally. It is frequently combined with other agents when monotherapy does not achieve target glucose levels.

Meglucon tablets should be stored at ambient temperature, below 25 °C, in the original blister pack or container to protect them from moisture and light. Keep the medication out of reach of children and do not use after the expiry date.

Meglucon is taken orally, usually with meals to reduce gastrointestinal discomfort. The tablets should be swallowed whole with a full glass of water. Patients should follow the dosing schedule prescribed by their healthcare provider.

The most serious risk is lactic acidosis, a rare but potentially fatal condition that can occur in patients with severe renal or hepatic impairment, dehydration, or excessive alcohol intake. Prompt medical attention is required if symptoms such as rapid breathing, muscle pain, or abdominal discomfort develop.

Meglucon is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), acute or chronic metabolic acidosis, including diabetic ketoacidosis, and in those with known hypersensitivity to metformin or any component of the formulation.